Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma

This study tests two types of nuclear medicine imaging scans — MIBG scanning and somatostatin receptor imaging — in children and young adults with neuroblastoma (a childhood cancer that typically starts in the adrenal glands or nerve tissue) to improve how accurately the cancer is detected and staged. **You may be eligible if...** - You are between 0 and 18 years old - You have been diagnosed with neuroblastoma (confirmed by biopsy or strongly suspected on clinical grounds) and imaging is planned - You have at least one tumor visible on standard CT or MRI scans - Your blood counts and organ function are within acceptable limits **You may NOT be eligible if...** - You have a known severe allergy to the imaging agents used in this study - You are pregnant or breastfeeding - You recently received high-dose chemotherapy, radiation, or a prior nuclear medicine treatment that could interfere with the scan results Talk to your doctor to see if this trial is right for you.